Pds Biotechnology Corp Stock Performance
| PDSB Stock | USD 1.26 0.01 0.79% |
The company holds a Beta of 1.8, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, PDS Biotechnology will likely underperform. At this point, PDS Biotechnology Corp has a negative expected return of -0.8%. Please make sure to check PDS Biotechnology's kurtosis, as well as the relationship between the day median price and relative strength index , to decide if PDS Biotechnology Corp performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Dividend Date 2019-03-18 | Last Split Date 2019-03-18 |
1 | Acquisition by Bloomquist Delyle W of 10000 shares of PDS Biotechnology at 9.8778 subject to Rule 16b-3 | 11/29/2024 |
2 | E2IPs Edge AI Sensing Platform with Machine Vision. An ST Micro based Edge AI platform | 12/12/2024 |
3 | Consumer Edge Reports Resale Market Outperforms Traditional Retail in 2024 | 12/17/2024 |
4 | Acquisition by Iliev Ilian of 9000 shares of PDS Biotechnology at 3.9 subject to Rule 16b-3 | 12/24/2024 |
5 | Dont Click TwiceNew Chrome, Edge, Safari Hack Attack Warning | 01/03/2025 |
6 | Edge AI Software Global Market Forecast to 2030 TinyML Deployment Offers Fresh Avenues for Edge AI Development | 01/06/2025 |
7 | Bigleaf Networks Unveils Pivotal 5G Connectivity Solution with BLR Edge 800W | 01/15/2025 |
8 | Acquisition by Glover Steve C of 9000 shares of PDS Biotechnology at 1.45 subject to Rule 16b-3 | 01/17/2025 |
9 | PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical ... | 02/05/2025 |
10 | Golden Corral Reinvents the Buffet with a Digital Overhaul | 02/11/2025 |
11 | PDS Biotech to Participate at B. Riley Securities Precision Oncology Radiopharma ... | 02/20/2025 |
12 | Acquisition by Glover Steve C of 9000 shares of PDS Biotechnology at 9.95 subject to Rule 16b-3 | 02/21/2025 |
13 | Calque Partners with EDGE Home Finance to Provide Buy-Before-You-Sell Programs That Convert Equity to Cash | 02/25/2025 |
| Begin Period Cash Flow | 73.8 M |
PDS |
PDS Biotechnology Relative Risk vs. Return Landscape
If you would invest 219.00 in PDS Biotechnology Corp on November 28, 2024 and sell it today you would lose (93.00) from holding PDS Biotechnology Corp or give up 42.47% of portfolio value over 90 days. PDS Biotechnology Corp is currently does not generate positive expected returns and assumes 5.5204% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than PDS, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PDS Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PDS Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PDS Biotechnology Corp, and traders can use it to determine the average amount a PDS Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1451
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PDSB |
Estimated Market Risk
| 5.52 actual daily | 49 51% of assets are more volatile |
Expected Return
| -0.8 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PDS Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PDS Biotechnology by adding PDS Biotechnology to a well-diversified portfolio.
PDS Biotechnology Fundamentals Growth
PDS Stock prices reflect investors' perceptions of the future prospects and financial health of PDS Biotechnology, and PDS Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PDS Stock performance.
| Return On Equity | -1.74 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 22.24 M | ||||
| Shares Outstanding | 37.41 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (40.08 M) | ||||
| Net Income | (42.94 M) | ||||
| Cash And Equivalents | 52.98 M | ||||
| Cash Per Share | 1.86 X | ||||
| Total Debt | 23.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (33.64 M) | ||||
| Earnings Per Share | (1.17) X | ||||
| Market Capitalization | 47.14 M | ||||
| Total Asset | 59.39 M | ||||
| Retained Earnings | (144.5 M) | ||||
| Working Capital | 45.43 M | ||||
| Current Asset | 39.11 M | ||||
| Current Liabilities | 4.54 M | ||||
About PDS Biotechnology Performance
By analyzing PDS Biotechnology's fundamental ratios, stakeholders can gain valuable insights into PDS Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PDS Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PDS Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.65) | (0.68) | |
| Return On Capital Employed | (1.08) | (1.14) | |
| Return On Assets | (0.65) | (0.68) | |
| Return On Equity | (1.89) | (1.80) |
Things to note about PDS Biotechnology Corp performance evaluation
Checking the ongoing alerts about PDS Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PDS Biotechnology Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology may become a speculative penny stock | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (42.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp currently holds about 52.98 M in cash with (33.64 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from businesswire.com: Calque Partners with EDGE Home Finance to Provide Buy-Before-You-Sell Programs That Convert Equity to Cash |
- Analyzing PDS Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PDS Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining PDS Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PDS Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PDS Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PDS Biotechnology's stock. These opinions can provide insight into PDS Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PDS Stock analysis
When running PDS Biotechnology's price analysis, check to measure PDS Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PDS Biotechnology is operating at the current time. Most of PDS Biotechnology's value examination focuses on studying past and present price action to predict the probability of PDS Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PDS Biotechnology's price. Additionally, you may evaluate how the addition of PDS Biotechnology to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |